Impurity Analysis Information

Your pharmaceutical quality is assured

Organic synthesis or cell culture (in the case of biotherapeutics) often leads to less than 100% production. Consequently, a range of impurities are made together with any medicine. In addition, impurities can come from anything within the production or packaging chain that the medicine comes into contact with. Regulatory authorities focus on the control of impurities and typically incorporate limits that restrict impurity levels present in active pharmaceutical ingredients (APIs) and drug formulations. Typically these impurities are divided into three classes: organic impurities, inorganic impurities, and residual solvents.

A range of analytical workflows and techniques are required for comprehensive impurity profiling, including; sample preparation, gas or liquid chromatography, mass spectrometry. Thermo Fisher Scientific has an extensive portfolio for comprehensive impurity profiling of pharmaceuticals to support your compliance testing.

Impurity Profiling of Pharmaceutical Starting Materials Using Gas Chromatography Coupled with High-Resolution Accurate Mass Spectrometry

Pharmaceutical impurities are unwanted chemicals present in starting and intermediate materials used in the manufacturing of active pharmaceutical ingredients (API) which, even in small amounts, can affect the efficiency of the pharmaceutical product and ultimately can pose health risks to patients.

Metoprolol and Select Impurities Analysis Using a Hydrophilic Interaction Chromatography Method with Combined UV and Charged Aerosol Detection

The drug metoprolol succinate USP is a selective beta-adrenoreceptor antagonist that reduces chest pain and lowers high blood pressure. Several pharmacopoeias (United States Pharmacopoeia, European Pharmacopoeia, and British Pharmacopoeia) have indicated acceptable levels of impurities allowed by drug manufacturers.

Pharmaceutical Impurity Profiling: Simple, Confident Analysis with New GC-MS Technology

Discuss how to overcome the challenges encountered in pharmaceutical intermediate impurity analysis, and how to deliver a new degree of confidence in the identification of unknown volatile and semi-volatile impurities.


Featured videos


Share